<DOC>
	<DOCNO>NCT00637845</DOCNO>
	<brief_summary>A double-blind study compare Esomeprazole Magnesium 40 mg daily Lansoprazole 30 mg twice daily control symptoms patient gastroesophageal reflux disease ( GERD ) continue heartburn symptom course therapy 30 mg twice daily Lansoprazole .</brief_summary>
	<brief_title>Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily Symptom Control Subjects With Persistent Gastrooesophageal Reflux Disease ( GERD )</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Subjects must report history heartburn symptom whilst lansoprazole 30 mg twice daily 30 day prior screen . Subjects must minimal cumulative heartburn score least 4 minimum 14 day , zero = none , one = mild , two = moderate , three = severe . subject history esophageal ulcer , esophageal stricture , esophageal neoplasm , gastric duodenal ulcer , significant gastric esophageal pathology judge clinically significant investigator . Subjects persistent heartburn symptom lansoprazole 30 mg twice daily period &gt; 6 month Subjects history severe hepatic insufficiency ( specifically , ChildsPugh Class C liver disease ) may adversely affect metabolism abd pharmacokinetics esomeprazole and/or lansoprazole .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Nexium</keyword>
	<keyword>Esomeprazole Magnesium</keyword>
	<keyword>Gastroesophageal Reflux Disease</keyword>
	<keyword>Heartburn</keyword>
</DOC>